Kaye S - Search Results

1

Chemotherapy for metastatic breast cancer-report of a European expert panel.

Crown J, Diéras V, Kaufmann M, von Minckwitz G, Kaye S, Leonard R, Marty M, Misset JL, Osterwalder B, Piccart M. Crown J, et al. Among authors: kaye s. Lancet Oncol. 2002 Dec;3(12):719-27. doi: 10.1016/s1470-2045(02)00927-0. Lancet Oncol. 2002. PMID: 12473512 Review.

2

Clinical benefit of new targeted agents in phase I trials in patients with advanced colorectal cancer.

Arkenau HT, Brunetto AT, Barriuso J, Olmos D, Eaton D, de Bono J, Judson I, Kaye S. Arkenau HT, et al. Among authors: kaye s. Oncology. 2009;76(3):151-6. doi: 10.1159/000195884. Epub 2009 Jan 23. Oncology. 2009. PMID: 19169046

3

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.

Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Iannone R, Kaye SB, de Bono JS, Wenham RM. Sandhu SK, et al. Among authors: kaye sb. Lancet Oncol. 2013 Aug;14(9):882-92. doi: 10.1016/S1470-2045(13)70240-7. Epub 2013 Jun 28. Lancet Oncol. 2013. PMID: 23810788 Clinical Trial.

4

Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

Ledermann JA, Hackshaw A, Kaye S, Jayson G, Gabra H, McNeish I, Earl H, Perren T, Gore M, Persic M, Adams M, James L, Temple G, Merger M, Rustin G. Ledermann JA, et al. Among authors: kaye s. J Clin Oncol. 2011 Oct 1;29(28):3798-804. doi: 10.1200/JCO.2010.33.5208. Epub 2011 Aug 22. J Clin Oncol. 2011. PMID: 21859991 Clinical Trial.

5

Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC).

Seifert H, Georgiou A, Alexander H, McLachlan J, Bodla S, Kaye S, Barton D, Nobbenhuis M, Gore M, Banerjee S. Seifert H, et al. Among authors: kaye s. Gynecol Oncol. 2015 Nov;139(2):216-20. doi: 10.1016/j.ygyno.2015.08.015. Epub 2015 Aug 28. Gynecol Oncol. 2015. PMID: 26318078

6

Weekly paclitaxel in the treatment of recurrent ovarian cancer.

Baird RD, Tan DS, Kaye SB. Baird RD, et al. Among authors: kaye sb. Nat Rev Clin Oncol. 2010 Oct;7(10):575-82. doi: 10.1038/nrclinonc.2010.120. Epub 2010 Aug 3. Nat Rev Clin Oncol. 2010. PMID: 20683437 Review.

7

Docetaxel in the management of ovarian cancer.

Blagden SP, Kaye SB. Blagden SP, et al. Expert Rev Anticancer Ther. 2005 Apr;5(2):203-14. doi: 10.1586/14737140.5.2.203. Expert Rev Anticancer Ther. 2005. PMID: 15877518 Review.

8

Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials.

Harrison ML, Gore ME, Spriggs D, Kaye S, Iasonos A, Hensley M, Aghajanian C, Venkatraman E, Sabbatini P. Harrison ML, et al. Among authors: kaye s. Gynecol Oncol. 2007 Sep;106(3):469-75. doi: 10.1016/j.ygyno.2007.05.008. Epub 2007 Jul 5. Gynecol Oncol. 2007. PMID: 17614127 Free PMC article.

9

Ovarian cancer: strategies for overcoming resistance to chemotherapy.

Agarwal R, Kaye SB. Agarwal R, et al. Nat Rev Cancer. 2003 Jul;3(7):502-16. doi: 10.1038/nrc1123. Nat Rev Cancer. 2003. PMID: 12835670 Review.

10

Ovarian cancer: progress and continuing controversies in management.

Moss C, Kaye SB. Moss C, et al. Eur J Cancer. 2002 Sep;38(13):1701-7. doi: 10.1016/s0959-8049(02)00161-2. Eur J Cancer. 2002. PMID: 12175685 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,485 results

Search Page